Yes, feels like something is going on. Nearly all of my shares have been borrowed so there is a bit of a battle going on between the long and the short side. Personally I think at the forthcoming AGM, item 4, relating to the issue of options to the CEO is very interesting. The exercise price is $0.782 but the vesting criteria is either of i) US$ 7.5 million of EBIT in any one year (that is EBIT not EBITDA) that is @ A$10 million or ii) The completion of a commercial deal with a pharmaceutical company to utilize Cogstate's technology for the triaging of patients into the prescription of an Alzheimer's disease modifying drug, AND the approval of the drug in question by the FDA.
You have to assume that either or both of these are achievable goals. If either were to occur we will be looking at a share price of at least A$ 2, in my opinion.
CGS Price at posting:
69.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)